When a cell will get able to divide, it shuts down its gene-reading equipment nearly fully.
“As cells put together to divide, they quickly shut down most gene studying, or transcription,” says Claudio R. Alarcón, PhD, affiliate professor of pharmacology at Yale College of Medication. “At that time, the cell must give attention to dividing.”
For many years, the mechanism behind that shutdown was solely partially understood. A brand new research co-led by Alarcón and Lilian Kabeche, PhD, affiliate professor of molecular biophysics and biochemistry at Yale College of Medication, identifies a lacking piece: an enzyme greatest identified for tagging RNA molecules that seems to be wired into the cell division equipment itself. The findings, recently published in Molecular Cell, could level towards new most cancers therapies.
An enzyme with a second job
The enzyme on the middle of the research is METTL3, which modifies RNA by attaching a small chemical tag. Scientists have lengthy identified these tags assist decide whether or not messenger RNA (mRNA) molecules are stabilized, transported, or damaged down. Alarcón’s lab beforehand found that METTL3 not solely impacts the destiny of mRNA molecules but in addition regulates how mRNA molecules are produced. It does this by tagging a small RNA known as 7SK.
“7SK is a scaffolding nuclear RNA that is essential to control transcription,” says Alarcón, a member of Yale Most cancers Biology Institute and Yale Most cancers Middle. “You’ll be able to consider 7SK as slightly sponge that sequesters transcription-elongating components—traps them—to allow them to’t promote transcription.”
Progress-stimulating components activate METTL3 to tag 7SK, which opens the lure. A protein advanced is launched, and the cell’s gene-reading machine will get the sign to advertise mRNA transcription. The newly generated mRNA molecules will then be translated into the proteins required for cell progress.
“What the work is exhibiting is that you should activate METTL3 to get the RNA off the chromosomes to have the ability to actually condense that DNA and segregate faithfully.”
The new paper shows this same chain reaction is triggered the moment a cell commits to division. An enzyme called CDK1 activates METTL3, which sets off the same cascade of events. However, in this case, the goal is to complete transcription and clear mRNA molecules from DNA, rather than making new proteins.
“What the work is showing is that you need to activate METTL3 to get the RNA off the chromosomes to be able to really condense that DNA and segregate faithfully,” says Kabeche, also a member of Yale Cancer Biology Institute and Yale Cancer Center. “It’s connecting an interphase process with the mitotic process. The mechanisms by which those two things were really connected weren’t understood.”
A question of timing
The window for all of this is narrow. “Mitosis only lasts about an hour,” Kabeche says. Cells have to condense their chromosomes, segregate them, and complete the whole process within a short period of time. “So it has to be very tightly controlled and very quick.”
Kabeche describes CDK1 as operating like a light switch: “When you have high enough CDK1 activity, it turns off METTL3. Then, CDK1 activity drops at the end of mitosis, and the switch goes the other way. Everything has to work exactly perfectly for it to look the way it’s supposed to.”
“As cells prepare to divide, they rapidly shut down most gene reading, or transcription. At that point, the cell needs to focus on dividing.”
So what happened when the researchers used the gene-editing tool CRISPR to prevent METTL3 from being activated by CDK1, or prevent 7SK from being modified by METTL3?
“You start making mistakes,” Alarcón says. “Chromosomes don’t segregate properly. You have lagging chromosomes. You can generate mutations. You can have all sorts of problems.”
Why it matters for cancer
A chromosome in the wrong cell creates what’s called aneuploidy, or a cell with too many or too few chromosomes. Kabeche, whose lab focuses on chromosomal instability in cancer, says aneuploidy is one of the defining features of tumors.
“In cancer cells, aneuploidy is highly correlated with poor patient prognosis, increased metastasis, and increased drug resistance,” she says.
Chromosomal instability is present in over 90% of solid tumors. METTL3 inhibitors already exist, and Kabeche sees potential in combining them with other drugs to overwhelm cancer cells. “You can think of it like heat,” she says. “You can tolerate a little, but if it’s 110 degrees in the desert, those cells are not going to survive. The goal is to push them past that point.”
Researchers studying METTL3’s role in cancer, neurodegeneration, and stem cell biology have historically explained its effects through post-transcriptional mechanisms, or changes to mRNA stability or splicing. Those explanations may have overlooked METTL3’s transcriptional mechanism, which was unknown until now.
Alarcón frames the paper as the start of a broader collaboration among cancer researchers. And Kabeche agrees.
“Because we’re in the Yale Cancer Biology Institute where all of the scientists work on different aspects of cancer, we can come together,” Kabeche says. “If we weren’t next to each other, I don’t think it would have been as fruitful.”
Source: Yale University
